Kyverna Therapeutics (KYTX) Free Cash Flow (2023 - 2026)
Kyverna Therapeutics (KYTX) posted Free Cash Flow of -$41.6 million for Q1 2026, down 20.11% on a QoQ basis from -$34.6 million in Q4 2025, and up 8.4% year-over-year from -$38.4 million in Q1 2025.
Kyverna Therapeutics (KYTX) Free Cash Flow (2023 - 2026) Analysis & Trends
Kyverna Therapeutics' Free Cash Flow history runs 4 years deep, the most recent figure standing at -$41.6 million for Q1 2026.
- Quarterly Free Cash Flow rose 8.4% year-over-year to -$41.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$151.0 million (down 11.04% YoY) and the FY2025 annual result came in at -$154.8 million, down 33.24% from the prior year.
- Free Cash Flow was -$41.6 million for Q1 2026 at Kyverna Therapeutics, down from -$34.6 million in the prior quarter.
- Across five years, Free Cash Flow topped out at -$11.1 million in Q2 2023 and bottomed at -$45.4 million in Q1 2025.
- A 4-year average of -$28.2 million and a median of -$28.5 million in 2024 frame the typical range for Free Cash Flow.
- Annual changes were most pronounced in 2024 — Free Cash Flow sank 146.51% — and 2025, when it grew 8.9%.
- Kyverna Therapeutics' Free Cash Flow stood at -$20.1 million in 2023, then plunged by 88.92% to -$38.0 million in 2024, then increased by 8.9% to -$34.6 million in 2025, then slipped by 20.11% to -$41.6 million in 2026.
- Business Quant data shows KYTX's Free Cash Flow at -$41.6 million in Q1 2026, -$34.6 million in Q4 2025, and -$42.8 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Free Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -19.58 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 158.09 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | -1.53 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 1.29 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 848.30 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -354.95 Mn |
| 10 | Kyverna Therapeutics | 440.57 Mn | 440.57 Mn | - | -41.60 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -41.60 Mn |
| Mar 31, 2026 | -41.60 Mn |
| Dec 31, 2025 | -34.64 Mn |
| Dec 31, 2025 | -34.64 Mn |
| Sep 30, 2025 | -42.82 Mn |
| Sep 30, 2025 | -42.82 Mn |
| Jun 30, 2025 | -31.95 Mn |
| Jun 30, 2025 | -31.95 Mn |
| Mar 31, 2025 | -45.42 Mn |
| Mar 31, 2025 | -45.42 Mn |
| Dec 31, 2024 | -38.02 Mn |
| Dec 31, 2024 | -38.02 Mn |
| Sep 30, 2024 | -28.48 Mn |
| Sep 30, 2024 | -28.48 Mn |
| Jun 30, 2024 | -24.09 Mn |
| Jun 30, 2024 | -24.09 Mn |
| Mar 31, 2024 | -25.61 Mn |
| Mar 31, 2024 | -25.61 Mn |
| Dec 31, 2023 | -20.13 Mn |
| Dec 31, 2023 | -20.13 Mn |